




# LGS RESEARCH MEETING OF THE MINDS



**ADVANCING EVIDENCE-BASED  
LGS CARE ACROSS THE LIFESPAN**



*July 21 - 22, 2025*

**LGS FOUNDATION<sup>®</sup>**  
LENNOX-GASTAUT SYNDROME  
[www.LGSFoundation.org](http://www.LGSFoundation.org)

# A Huge Thank You to Our Research Conference Sponsors!

## Patron Supporter

Lundbeck



## Premier Supporters



Inspired by **patients.**  
Driven by **science.**



**Jazz** Pharmaceuticals.



**HARMONY**  
BIOSCIENCES

**ASSERTIO**

## Partners



**LivaNova**  
Epilepsy



**NEURELIS**<sup>TM</sup>

## Supporter

**GeneRx**

# Meeting Goals and Objectives

## Meeting Goals:

- Convene caregivers, health care providers, researchers, and industry partners to discuss how we advance evidence-based LGS care across the lifespan.
- Guide the LGS Foundation's funding strategy in 2025 and beyond through information learned from this meeting.

## Learning Objectives:

At the end of the meeting, the attendees should:

- Understand various stakeholder perspectives on evidence-based care in LGS.
- Evaluate the current methods for diagnosing and treating LGS across the lifespan and understand gaps in care.
- Learn about methods for conducting evidence-based research in LGS and associated DEEs.
- Analyze ongoing research efforts to create new evidence for LGS treatment.
- Discuss short-term and long-term efforts to improve evidence-based care in LGS and create clear next steps to work on.

## Special Thanks to Our Organizers:



Elaine Wirrell, MD  
Mayo Clinic, Rochester, MN



Scott Perry, MD  
Cook Children's Hospital, TX



Fabio Nascimento, MD  
Washington University, MO



Renee Shellhaas, MD, MS  
Washington University  
School of Medicine



Elizabeth Gerard, MD  
Northwestern Medicine



Jennifer Gelinas, MD, PhD  
University of California Irvine



Pete Crino, MD, PhD  
University of Maryland,  
School of Medicine

*Thank you to our amazing volunteers whose support helped this meeting run smoothly—your efforts mean the world!*

# Research Conference Agenda

## Monday, July 21<sup>st</sup>, 2025

7:00am	<b>BREAKFAST</b>	Stenton
<b>SESSION 1:</b>	<b>How do we currently manage LGS across the lifespan, where do we fall short, and what can we learn from other disease states?</b>	Main Ballroom
8:00am	Welcome & Opening Remarks <i>Fred Roedl, MBA, LGS Foundation Board Chair</i>	
8:05am	<b>Introduction:</b> What is evidence-based care and why do we want it? <i>Tracy Dixon-Salazar, PhD, LGS Foundation Executive Director</i>	
8:25am	What it is like caring for a child with LGS <i>Jennifer Fischer, Caregiver of a Child with LGS</i>	
8:30am	What it is like caring for an adult with LGS <i>Stephen Feather, Caregiver of an Adult with LGS</i>	
8:35am	How do we currently manage LGS in children? Where do we fall short? <i>Moderator: Elaine Wirrell, MD, Mayo Clinic</i>	
8:55am	How do we currently manage LGS in adults? Where do we fall short? <i>Moderator: Fabio Nascimento, MD, University of Washington</i>	
9:15am	Developing Evidence-Based Guidelines - The Cystic Fibrosis Experience <i>Michael Schechter, MD, MPH, Virginia Commonwealth University</i>	
9:45am	<b>BREAK</b>	
10:00am	How do we currently manage transition of care? Where do we fall short in the DEEs? <i>Ann Tilton, MD, Child Neurology Foundation</i>	Main Ballroom
10:30am	What can we learn from transition of care programs for congenital heart disease? <i>Emily Ruckdeschel, MD, Children's Hospital of Philadelphia</i>	
11:00am	Panel Discussion: How do we prioritize the gaps in evidence-based care in LGS? <i>Moderators: Renee Shellhaas, MD, MS, Washington University School of Medicine Scott Perry, MD, Cook Children's Hospital</i>	
12:00pm - 1:00pm	<b>LUNCH BREAK</b>	Stenton

# Research Conference Agenda

## Monday, July 21<sup>st</sup>, 2025

### SESSION 2A: **What methods can we use to advance evidence-based care across the LGS lifespan?**

Main  
Ballroom

- 1:00pm Welcome Back  
*Fred Roedl, MBA, LGS Foundation Board Chair*
- 1:05pm From Guessing to Knowing: Changing the Path for LGS Across the Lifespan  
*Kathy Leavens, LGS Foundation Senior Director of Programs*
- 1:10pm **Introduction:**  
What methods can we use to advance evidence-based care across the LGS lifespan?  
*Scott Perry, MD, Cook Children's Hospital*
- 1:15pm Building a Team - Pediatric Epilepsy Research Consortium LGS Special Interest Group as an Example of Research Collaboration  
*Debopam Samanta, MD, University of Arkansas Medical Science*
- 1:35pm Growing the Team - Training Adult Providers to Care for Rare Epilepsies  
*Elizabeth Gerard, MD, Northwestern Medicine*
- 1:55pm Barriers to Multidisciplinary Complex Care in Adulthood  
*Alexa King, MD, Northwestern Medicine*
- 2:15pm Building Consensus: Where are we now?  
*Juliet Knowles, MD, PhD, Stanford University*

### 2:35pm **BREAK**

- 3:00pm Using the Electronic Health Records (EHR) to Generate Natural History  
*Jillian McKee, MD, PhD, Children's Hospital of Philadelphia*
- 3:20pm Mining Big Data to Determine Evidence-Based Care  
*Zach Grinspan, MD, MS, Weill Cornell School of Medicine*
- 3:40pm Acquiring Data from the Hospital IT's View - Barriers to Implementation  
*George Morris, MBA, VP Chief Data & Analytics Officer, Cook Children's Hospital*
- 4:00pm Putting the Patient In Charge  
*Michael Hammer, PhD, University of Arizona*
- 4:20pm Building the Best Note - Panel Discussion  
*Moderator; Scott Perry, MD, Cook Children's Hospital*

Main  
Ballroom



# Research Conference Agenda

**Monday, July 21<sup>st</sup>, 2025**

**SESSION 2B: Industry Partner Perspectives**

Main  
Ballroom

- 4:40pm **Introduction:**  
Evidence-Based Care from Industry Partner Perspective  
*Tracy Dixon-Salazar, PhD, LGS Foundation Executive Director*
- 4:45pm LGS Trials Past, Present, Future  
*Dennis Dlugos, MD, Lundbeck*
- 4:55pm One Syndrome, Many Causes: Understanding the diverse genetics of LGS *Karthik Rajasekaran, PhD, Jazz Pharmaceuticals*
- 5:05pm LGS & Fintepla: What's New, What's Next?  
*Amelie Lothe, PhD, UCB Pharmaceuticals*
- 5:20pm Novel Drug Formulations for Patients Suffering with DEEs  
*Howard Franklin, MD, Assertio Pharmaceuticals*
- 5:30pm Clemizole (EPX-100): A Novel Treatment in Development for LGS. *Anna Jeong, MD, Senior Medical Director, Harmony Biosciences*
- 5:40pm Wrap-Up  
*Tracy Dixon-Salazar, PhD, LGS Foundation Executive Director*

6:00pm **RECEPTION DINNER**

Courtyard

## LGS PROFESSIONAL RESOURCES

- Educational Resources (e.g. CMEs)
- Support for your Patients-Families
- Research Funding Opportunities

### What We Offer:

- 12,000+ community members in 23 countries
- Funding for cutting-edge LGS research
- Resources for LGS professionals including;
  - LGS ICD-10 Code Use for Research
  - PERC LGS Special Interest Group Info
  - Comprehensive Care Center Listings
  - LGS Collaborative Research Network

**LGS FOUNDATION**  
LENNOX-GASTAUT SYNDROME

Scan to  
Learn More



**LGS FOUNDATION**  
LENNOX-GASTAUT SYNDROME

# Research Conference Agenda

**Tuesday, July 22<sup>nd</sup>, 2025**

7:00am	<b>BREAKFAST</b>	Stenton
<b>SESSION 3:</b>	<b>What do we need to do now to advance LGS evidence-based care across the lifespan?</b>	Main Ballroom
8:00am	Welcome Back <i>Tracy Dixon-Salazar, PhD, LGS Foundation Executive Director</i>	
8:05am	<b>Introduction:</b> What do we need to do now to advance evidence-based care across the lifespan? <i>Jennifer Gelinas, MD, PhD, University of California Irvine</i>	
8:15am	What evidence is needed now for children in order to make decisions? <i>Bertha Guillen, Caregiver of a Child with LGS</i>	
8:20am	What evidence is needed now for adults in order to make decisions? <i>Jamie Riley, Caregiver of an Adult with LGS</i>	
8:25am	Learning from Animal Models: Where Are We Limited? <i>Juliet Knowles, MD, PhD, Stanford University</i>	
8:45am	Identifying Genetic Markers of LGS and Associated DEEs in Children and Adults: Are All Genetic Conditions the Same? <i>Pete Crino, MD, PhD, University of Maryland</i>	
9:05am	Knowing the cause of your child's seizures: is it genetic? <i>Tracy Dixon-Salazar, PhD, LGS Foundation Executive Director</i> <i>Tiffany Johnson, MBA, LGS Foundation Director of Development</i> <i>Mary Freivogel, MS, CGC, GeneDx</i>	
9:25am	LGS Learn from Every Patient Database <i>Tracy Dixon-Salazar, PhD, LGS Foundation Executive Director</i>	
9:35am	Identifying EEG/Network Markers of DEEs and LGS in Children and Adults <i>Jennifer Gelinas, MD, PhD, University of California Irvine</i>	
9:55am	Identifying the Best Stimulation Approaches to Seizures <i>John Rolston, MD, PhD, Brigham &amp; Women's Hospital, Harvard Medical School</i>	
10:15am	<b>BREAK</b>	
10:30am	Defining LGS in Undiagnosed Adults: How Do We Find Them? <i>Chris McGraw, MD, PhD, Northwestern Medicine</i>	Main Ballroom
10:50am	Measuring Cognition and Behavior in LGS <i>Kette Valente, MD, PhD, University of Sao Paulo</i>	
11:10am	Characterizing Sleep in LGS <i>Gita Gupta, MD, John Hopkins University</i>	

# Research Conference Agenda

## Tuesday, July 22<sup>nd</sup>, 2025

11:30am	Developing Patient Centric Seizure Action Plans for DEEs - One size doesn't fit all <i>Eric Pina Garza, MD, FAES, Centennial Children's Hospital, Vanderbilt University</i>	Main Ballroom
11:50am	Wrap-Up <i>Jennifer Gelinas, MD, PhD, University of California Irvine</i>	
11:55am	Thinking Ahead to Session 4 <i>Tracy Dixon-Salazar, PhD, LGS Foundation Executive Director</i>	
12:00pm - 1:00pm	<b>LUNCH BREAK</b>	Stenton
<b>SESSION 4: Where do we go from here?</b>		Main Ballroom
1:00pm	Welcome Back/Introduction to Breakout Groups <i>Tracy Dixon-Salazar, PhD, LGS Foundation Executive Director</i>	
1:15pm	Transition to Breakouts	
1:20pm	<b>Breakout Discussions</b> <ul style="list-style-type: none"><li>• Discussion Group 1 -Main Ballroom</li><li>• Discussion Group 2 -Foyer Meeting Area</li><li>• Discussion Group 3 -Mount Vernon</li></ul>	
2:20pm	Transition to Main Ballroom	Main Ballroom
2:25pm	Discussions - What did we learn and what do we do next? <i>Moderator: Scott Perry, MD, Cook Children's Hospital</i>	
3:25pm	Meeting Wrap-Up <i>Tracy Dixon-Salazar, PhD, LGS Foundation Executive Director</i>	
3:35pm	Closing Remarks <i>Fred Roedl, MBA, LGS Foundation Board Chair</i>	

*"Because we commit our minds to science and our hearts to compassion, even the most complex challenges—like LGS—have become opportunities for hope and change."*

*-Tracy Dixon-Salazar, PhD*





## A NEW WAVE OF HOPE

### Join Us in the Quest to Help Advance Treatment for Developmental and Epileptic Encephalopathies (DEE)

#### ABOUT THE DEEp OCEAN STUDY

The DEEp OCEAN clinical study is assessing the safety, efficacy, and tolerability of the investigational drug in the treatment of seizures in children and adults with DEE, a severe form of epilepsy that affects learning and development.

All study-related visits, tests, and medications will be provided at no cost. Where regulations allow, participants and caregivers will be fairly compensated for their travel, time, and effort for the duration of the clinical study.



#### WHY PARTICIPATE IN CLINICAL RESEARCH?

There's no guarantee that participants will get a health benefit from being in the study. You might have the opportunity to learn more about your loved one's condition and play a role in defining future treatment options for the DEE community. The decision to participate is completely voluntary and a personal choice.

#### Interested in Learning More?


Visit [www.DEEpDEEstudy.com](http://www.DEEpDEEstudy.com) for more information about how to participate today!

For additional details please visit [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) using the study ID: NCT06719141

#### Qualified Participants:

- Have been diagnosed with a Developmental and Epileptic Encephalopathies (DEE), such as Lennox-Gastaut Syndrome (LGS) or other.
- Are between the ages of 2 and 65 years old.
- Have experienced seizure onset between:
  - Birth and 8 years old for people with LGS
  - Birth and 5 years old for people with DEE (other)
- Have an average of 4 seizures per month during the last 3 months.
- Are willing and able or have a caregiver who can maintain study diaries throughout the DEEp OCEAN study.

Additional study requirements to participate will apply. A study representative will discuss them with you.



#### SITE CONTACT INFORMATION:



**There is always more to be done**

Our commitment to improving the lives of people living with severe diseases runs deep. Our work doesn't stop when we close the lab door or analyze the last sample. Always looking for the next discovery, the next innovation — now and into the future.

To learn more, visit [www.ucb-usa.com](http://www.ucb-usa.com)  
© 2025 UCB, Inc. All rights reserved.

 Inspired by patients.  
Driven by science.

## Transforming Lives. Redefining Possibilities.



Jazz Pharmaceuticals is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options.

 **Jazz Pharmaceuticals**  
[www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com)

© 2023 Jazz Pharmaceuticals plc. All rights reserved. US-NEU-2300041



**DEFINE YOUR NEU NORMAL.**

 DISCOVER THE WAYS WE ARE INNOVATING LIFE-CHANGING TREATMENTS THAT EMPOWER PEOPLE TO DEFINE THEIR NEU NORMAL.

 **NEURELIS™**

NEURELIS and the NEURELIS logo are trademarks or registered trademarks of Neurelis, Inc.  
© Neurelis, Inc. 2022. All rights reserved.  
US-PRC-22-00219 09/22

SCAN OR VISIT [NEURELIS.COM/NEUNORMAL](http://NEURELIS.COM/NEUNORMAL)

## Help Shape the Future of LGS Care — At No Cost to Your Patients

### Support Better Outcomes Through:

#### Streamlined Medical Record Access

Easily consolidate patient health data in a secure, digital account — empowering families and enhancing care coordination.

#### Informed Clinical Decision-Making


Support data-driven care by contributing to a centralized repository of real-world LGS insights.

#### Collaborative Research

Participate in a global effort to uncover LGS patterns, improve diagnostics, and accelerate therapeutic discoveries.

Scan to Learn How Your Patients Can Enroll

 **LGS FOUNDATION™**  
**LEARN FROM EVERY PATIENT DATABASE**  
Your Voice is Key for the Future of LGS Treatments



**LivaNova**  
**Epilepsy**





is a proud sponsor of the

**LGS FOUNDATION<sup>®</sup>**  
LENNOX-GASTAUT SYNDROME



You're focused on  
the moments that  
matter. *So are we.*

If you or someone you care about is living with Lennox-Gastaut syndrome (LGS), consider the Lighthouse clinical study.



### About the Lighthouse Clinical Study

The purpose of the Lighthouse clinical study is to evaluate the safety and efficacy of the investigational medication, clemizole, as an additional therapy to potentially lower the number of seizures in children and adults living with Lennox-Gastaut syndrome (LGS). If someone you care about has frequent seizures from LGS, even when taking antiseizure medication(s), this clinical study may be an option.

The investigational medication, clemizole, is an oral solution that will be administered twice a day during the study. The study may last up to 3 1/2 years, including both clinic visits and phone calls.



©2025 Harmony Biosciences  
EPX-100\_Harmony\_Rare Epilepsy\_Digital Ad Template\_US\_EN\_v1.1\_28MAY2025

1 Year  
**365 Opportunities**

**Cure  
LGS  
Research  
Grants**

365

No Calls  
No Deadlines  
Submit Anytime

**LGS FOUNDATION<sup>®</sup>**  
LENNOX-GASTAUT SYNDROME



The LGS Foundation reviews unsolicited basic, translational, and clinical research proposals year round. Priority areas in 2025 are sleep, expressive communication, and EEG evolution in LGS.



#### Level 1: \$25,000

May be paid over one year or two. Indirect costs are not permitted. International applicants are welcome to apply.



#### Level 2: \$50,000

May be paid over one year or two. Indirect costs are not permitted. International applicants are welcome to apply.



#### Level 3: \$75,000

May be paid over one year or two. Indirect costs are not permitted. International applicants are welcome to apply.

Scan to  
Learn More



**LGS FOUNDATION<sup>®</sup>**  
LENNOX-GASTAUT SYNDROME



# LGS FOUNDATION<sup>®</sup>

## LENNOX-GASTAUT SYNDROME



### Our Vision:

To end the suffering and devastation caused by LGS.

### Our Mission:

The Lennox-Gastaut Syndrome (LGS) Foundation is a nonprofit organization dedicated to improving the lives of individuals impacted by LGS through advancing research, awareness, education, and family support.

### Our Pillars to Success:

To accomplish our mission we must:

- Support, empower, and educate our community
- Accelerate research
- Raise awareness and build community
- Build and strengthen our organization

### Our Theory of Change:

If we create meaningful, impactful, patient-driven programs guided by our pillars, we will improve the lives of those impacted by LGS.

Get Involved: **Volunteer** **Fundraise** **Donate**

### Visit Our Website

E-mail: [info@LGSFoundation.org](mailto:info@LGSFoundation.org)  
Phone: 718-374-3800



Follow Us on Social Media!



[www.LGSFoundation.org](http://www.LGSFoundation.org)